Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. - Wikidata - awgldk - TriplyDB

Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

http://www.wikidata.org/entity/Q30566518

about

Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries The role of technical assistance in expanding access to Xpert(®) MTB/RIF: experience in sub-Saharan Africa.Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in Uganda.Implementing rapid testing for tuberculosis in Mozambique Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects Comparative meta-analysis of tuberculosis contact investigation interventions in eleven high burden countries.Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation Rollout of Xpert(®) MTB/RIF in Northwest Cambodia for the diagnosis of tuberculosis among PLHA.Evaluation of the implementation of the Xpert® MTB/RIF assay in Fiji Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.BUTIMBA: Intensifying the Hunt for Child TB in Swaziland through Household Contact Tracing.Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program.Diagnostics for Developing Countries.Mixed impact of Xpert(®) MTB/RIF on tuberculosis diagnosis in Cambodia Policy to practice: impact of GeneXpert MTB/RIF implementation on the TB spectrum of care in Lilongwe, Malawi.Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination.Active Tuberculosis Case Finding in Port-au-Prince, Haiti: Experiences, Results, and Implications for Tuberculosis Control Programs Cost-effectiveness thresholds: pros and cons.Performance of a molecular assay to detect Mycobacterium tuberculosis complex DNA in clinical specimens: multicenter study in Brazil.Evaluation of the Cepheid Xpert MTB/RIF assay.The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up.Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening Pandemic-related health behavior: repeat episodes of influenza-like illness related to the 2009 H1N1 influenza pandemic.Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan Regulatory In Vitro Diagnostics Landscape in Africa: Update on Regional Activities.Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India.Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana.Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?

P2860

Q26740240-36808B43-B16F-4BB1-AA8E-8460D6A6CBC3 Q26778619-FECF22EB-0267-4D9A-B1CA-3EC2A9EF285D Q27010874-BFEB5DE7-D5A2-4989-827A-2BC8ACE2DFA1 Q28548369-39C0DE87-86E3-4C90-B319-76B75EEFAB2F Q28551561-87319634-7CD4-4081-920B-6E85D0BA4632 Q30152120-E9A08E97-EBE0-4396-8203-539942F3322F Q33629698-E9647938-1659-405C-812C-CA06937E20D3 Q33906816-D9B0598B-B961-4618-91B0-3A76859F9233 Q34098274-1D0E265D-5E34-4938-B08D-F490727FD480 Q34184138-1D2D3C7E-B68B-48D8-BC54-1AEE630A277A Q35120011-3FCED057-6A1F-4CD5-ADBE-89A1534C9A88 Q35197235-6618C78D-DE7E-4419-9169-7929BE57394A Q35220100-9EB09710-FED8-49A9-9540-93614AFA22B4 Q35804971-4905E20B-E601-4D82-8F36-144BE413A43B Q35944047-21940B09-3D94-4B7E-ABE6-9B0CCCB89167 Q35944859-0A1C2311-A70B-48C5-81C1-A59594C7C616 Q36094215-DA5C943D-746F-4CB6-AA40-E48E99A3350D Q36159840-9C7C0020-958C-4049-8B8E-99D19FE446AB Q36255753-879C5A63-42AB-4E90-A6C5-4B78A948F938 Q36275494-6BA85DAC-8063-4669-9236-7CA50D327EC4 Q36335270-2E575851-DC0F-4F31-A93D-CC195F646B85 Q37020517-595FFDAB-2B48-4878-B49D-1114808F5D85 Q37023865-CBC59B87-68A2-456F-B978-23A665ACB260 Q37077460-7E4DA4CE-26A2-4E91-A01D-3FC4E189DD7B Q37271273-0DF0985F-1882-4636-9B02-A03A882045F1 Q37498173-DE2AB541-99F4-474B-B521-C928622C9CC9 Q37626263-1CA68DB6-A065-435F-8856-BFBF71B08737 Q38265418-4F63A75D-A901-418B-9114-479A177D4C4F Q38399097-64A04AEE-564D-4CEE-8E57-67C740F8DB5E Q38582633-0A5B4E88-F52B-4220-8453-61AF86C94954 Q38615927-2AE1888A-11A9-4EBE-B019-F5FE515F8A72 Q38623426-D0F44957-2C11-4944-99D1-A40450F0BC9D Q38645708-5578B22A-3BF2-4024-BFAC-BAEFCBFF0ED5 Q38654576-748FD1D6-510B-432E-9AA1-9AF0583AFD1D Q38661821-7809AEA3-54C3-49E3-BA9B-01A5D44B13DA Q39237840-574BB4FC-4A07-47F7-88AA-D53D8DBF9433 Q39291335-B5CA50EF-7907-4093-A6DC-6ED0447A2707 Q40341517-49BACB46-8486-485E-8545-7E591C82492F Q40487862-AAAA4265-939E-4572-9AE5-CB2B080244A4 Q42356270-60879F2E-9ED4-4F6B-AC91-920F3893CFEC

P2860

Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

http://www.wikidata.org/entity/Q30566518

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Results from early programmati ...... RIF testing in nine countries.

@ast

Results from early programmati ...... RIF testing in nine countries.

@en

type

label

Results from early programmati ...... RIF testing in nine countries.

@ast

Results from early programmati ...... RIF testing in nine countries.

@en

prefLabel

Results from early programmati ...... RIF testing in nine countries.

@ast

Results from early programmati ...... RIF testing in nine countries.

@en

P1433

Q30566518-07698C83-AE01-4C63-94BD-F2DFF5BED6A0

P1476

Q30566518-05F67D51-1216-4AB9-9F20-E3CD81B62889

P2093

Q30566518-0B6211EC-CFBA-440C-BDE6-0D5B5139379A

Q30566518-22CE654A-6E58-441C-B3E5-1150EBEAADC1

Q30566518-4CEFD4C2-269E-4F63-AF69-A41B1831144C

Q30566518-5725C10C-BB7A-451A-B7C7-44AEB05EBFE0

Q30566518-64F8EC54-2EF0-4B15-96C0-BA44B4746810

Q30566518-7D2D2AC1-C571-44F9-A30C-6A55FEA78113

Q30566518-8D52F8F8-B82E-47E8-AB29-3BEDA3198696

Q30566518-A034735A-CDBB-4890-981D-8E53E898D6FD

Q30566518-A4FF18E2-5BC3-4900-A0F2-30093BFD95C7

Q30566518-C4388511-1D78-4D9B-88A3-EB4826CAA605

P2860

Q30566518-14124779-AA55-45EF-8F98-24547B9A5951

Q30566518-1EFC72BD-FE38-48CA-B048-B0DFF6335FE2

Q30566518-24D15E53-56D4-484D-AF76-EC29737C2D1B

Q30566518-2799AC48-40D3-44C9-AEE1-6B54255AE87F

Q30566518-2D1BF37E-BA4B-4924-826A-3A2786458EDD

Q30566518-51728498-99AD-4687-B7FA-32FB0EA6F7A3

Q30566518-6096F0DE-0A51-42D1-9912-CA5F424FEEF6

Q30566518-687FEB3D-8B42-4444-B500-93EF9A0708F7

Q30566518-749F07D3-0465-4BDC-830D-ED34289C76C0

Q30566518-8839695E-DF9D-4EDC-AE07-5523427F0304

P2888

Q30566518-BC0E61D7-DF3B-4513-A30B-FEA37F635A6A

P304

Q30566518-FA17B7AB-585C-4553-B1A3-2DEFADBD4B76

P31

Q30566518-4CCD2D34-C151-46A0-954D-3F4FC691AC72

P356

Q30566518-31940889-6EB8-48D7-8848-C872A0560E0E

P478

Q30566518-E1B18A15-1C8D-4671-ACDA-DDF378B4E108

P50

Q30566518-54258075-0E98-48C7-A6B8-3E279D17EABB

Q30566518-B00DCAFA-956B-4671-92BA-F11A3E9DD1CF

P577

Q30566518-F261397C-A3E4-4CA0-8619-2B7B00805004

P5875

Q30566518-38229D0B-8AB1-4AD0-98C3-E0182FB0F5AA

P6179

Q30566518-EEC71F71-2795-486A-90B8-3CFADC13CFA7

P698

Q30566518-B339675C-3EB2-464D-B379-03074827D0E7

P932

Q30566518-DED3A0F1-0804-4C33-A3AB-4213947623A6

P356

P1433

BMC Infectious Diseases

P1476

Results from early programmati ...... RIF testing in nine countries.

@en

P2093

Ahmed Bedru

http://www.w3.org/2001/XMLSchema#string

Andrei Mosneaga

http://www.w3.org/2001/XMLSchema#string

Andrew J Codlin

http://www.w3.org/2001/XMLSchema#string

Bishwa Rai

http://www.w3.org/2001/XMLSchema#string

E Jane Carter

http://www.w3.org/2001/XMLSchema#string

Emmanuel Andre

http://www.w3.org/2001/XMLSchema#string

Lucica Ditiu

http://www.w3.org/2001/XMLSchema#string

Lucie Blok

http://www.w3.org/2001/XMLSchema#string

Mark A Micek

http://www.w3.org/2001/XMLSchema#string

Miranda Brouwer

http://www.w3.org/2001/XMLSchema#string

P2860

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

Point-of-care diagnosis of tuberculosis: past, present and future

Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis

Rapid molecular detection of tuberculosis and rifampin resistance

Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.

Novel methodology to assess sputum smear microscopy quality in private laboratories.

GeneXpert--a game-changer for tuberculosis control?

Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis

High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.

P2888

P304

2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-14-2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259565191

http://www.w3.org/2001/XMLSchema#string

P6179

1027267173

http://www.w3.org/2001/XMLSchema#string

P698

24383553

http://www.w3.org/2001/XMLSchema#string

P932

3898850

http://www.w3.org/2001/XMLSchema#string